Brief: Tonix Pharmaceuticals - Prelim Q3 Net Revenue From Product Sales $3.3 Million - SEC Filing
27/10/2025 11:04
Oct 27 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS - PRELIM Q3 NET REVENUE FROM PRODUCT SALES $3.3 MILLION - SEC FILING TONIX PHARMACEUTICALS - TO LAUNCH TONMYA FOR FIBROMYALGIA BY END OF NOV 2025 - SEC FILING Source text: [ID:n0001999371-25-016108] Further company coverage: TNXP.O
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview